好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Limbic and Striatal Atrophy Corresponds to Regional Gene Expression in LGI1-IgG Autoimmune Encephalitis
Autoimmune Neurology
P3 - Poster Session 3 (11:30 AM-12:30 PM)
1-019

To characterize regional brain atrophy patterns, evaluate their association with regional leucine-rich glioma-inactivated-1 (LGI1) gene expression, and identify clinical predictors of hippocampal atrophy in LGI1-IgG autoimmune encephalitis (AE).

Residual brain atrophy associates with worse functional outcomes in LGI1-AE. The regional distribution of atrophy and its clinical determinants remain incompletely characterized.

This observational study compared regional brain volumes in an LGI1-AE cohort versus age-and-sex matched healthy controls (HC) and patients with Alzheimer’s disease (AD). LGI1 gene expression was derived from the Allen Human Brain Atlas. Multivariable linear regression and generalized linear models were used for association studies.

A total of 55 LGI1-AE patients were included. Median age was 68 years (IQR 62.5, 74.2) at volumetric analysis, after a median of 19 months (IQR 11, 45) from symptom onset. Compared to HC and AD, LGI1-AE had greater regional atrophy of the hippocampus, medial temporal lobe, insula, caudate, and putamen (p<0.002). Longitudinal analyses (n=17) demonstrated hippocampal and pallidal volume decline, remaining significant after co-variate adjustment. Regions with greatest differential atrophy, relative to comparators, corresponded with higher LGI1 gene expression (Spearman ρ = 0.7, p=0.005). Severe cognitive deficits at diagnosis (i.e., higher clinical dementia rating [CDR], β= -0.56; p=0.002) and longer disease duration at time of MRI (β= -0.01; p=0.001) independently predicted total hippocampal volume (R2 = 0.31). Smaller temporal (p=0.01), frontal (p=0.04), and parietal (p=0.03) volumes were associated with a higher proportion of impaired neuropsychological tests.

LGI1-AE is associated with a distinct pattern of limbic and striatal atrophy that differs from AD and aligns with regional LGI1 expression, supporting a model of selective network vulnerability involving limbic and striatal circuits. Greater baseline cognitive impairment and longer disease duration independently associated with hippocampal atrophy, underscoring the potential importance of early diagnosis and treatment to limit structural brain injury.

Authors/Disclosures
Andreu Vilaseca-Jolonch, MD
PRESENTER
Dr. Vilaseca-Jolonch has received research support from Fundación Martín Escudero.
Albert Aboseif, DO Dr. Aboseif has received research support from the Eugene & Marcia Applebaum Fellowship Grant.
Laura Cacciaguerra, MD, PhD (Mayo Clinic) Dr. Cacciaguerra has nothing to disclose.
Sravya Kondrakunta, PhD Dr. Kondrakunta has nothing to disclose.
Naveen K. Paramasivan, MD (Mayo Clinic) Dr. Paramasivan has nothing to disclose.
Andrea Stabile, MD Dr. Stabile has nothing to disclose.
Anuja R. Patil, MD, DM (26, Dept of Neurology, 3rd floor) Dr. Patil has nothing to disclose.
Xiaoyang Li, MD Dr. Li has nothing to disclose.
Pallab Sarker (Mayo Clinic) Pallab Sarker has nothing to disclose.
Luke Christenson Mr. Christenson has nothing to disclose.
Benjamin H. Brinkmann, PhD (Mayo Clinic) Dr. Brinkmann has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. Dr. Brinkmann has stock in Cadence Neuroscience. The institution of Dr. Brinkmann has received research support from Epilepsy Foundation of America. The institution of Dr. Brinkmann has received research support from National Institutes of Health. The institution of Dr. Brinkmann has received research support from National Institutes of Health. The institution of Dr. Brinkmann has received research support from UNEEG A/S. The institution of Dr. Brinkmann has received research support from Seer Medical Pty. The institution of Dr. Brinkmann has received research support from Neurelis Inc. Dr. Brinkmann has received intellectual property interests from a discovery or technology relating to health care.
Christopher Schwarz The institution of Christopher Schwarz has received research support from NIH.
Kejal Kantarci, MD (Mayo Clinic) The institution of Dr. Kantarci has received research support from Eli Lilly. The institution of Dr. Kantarci has received research support from NIH. The institution of Dr. Kantarci has received research support from ADDF. The institution of Dr. Kantarci has received research support from Eisai. The institution of Dr. Kantarci has received research support from BioArctic.
Andrew McKeon, MD (Mayo Clinic) The institution of Dr. McKeon has received research support from National Institutes of Health. Dr. McKeon has received intellectual property interests from a discovery or technology relating to health care. Dr. McKeon has received intellectual property interests from a discovery or technology relating to health care. Dr. McKeon has received publishing royalties from a publication relating to health care.
Anastasia Zekeridou, MD, PhD, FAAN (Neuroimmunology Laboratory, Mayo Clinic) The institution of Dr. Zekeridou has received research support from Roche/Genentech. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care.
Michael Basso, PhD Dr. Basso has nothing to disclose.
Dean M. Wingerchuk, MD, FAAN (Mayo Clinic) Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Meyer Squibb. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abcuro. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wolters Kluwers.
Sarosh R. Irani, MD, PhD, FRCP, FEAN (Mayo Clinic) Dr. Irani has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Alexion, Argenex, Atheneum, AZ, Clarivate, IQVIA, BioHaven therapeutics. Dr. Irani has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion US, Amgen, Argenx . Dr. Irani has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Brain. The institution of Dr. Irani has received research support from Amgen. Dr. Irani has received intellectual property interests from a discovery or technology relating to health care. Dr. Irani has received intellectual property interests from a discovery or technology relating to health care.
Sean J. Pittock, MD, FAAN (Mayo Clinic Dept of Neurology) Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. The institution of Dr. Pittock has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion/AstraZeneka. The institution of Dr. Pittock has received research support from NIH. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received publishing royalties from a publication relating to health care.
Burcu Zeydan, MD (Mayo Clinic) The institution of Dr. Zeydan has received research support from National Institutes of Health.
Divyanshu Dubey, MD, FAAN (Mayo Clinic) The institution of Dr. Dubey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. The institution of Dr. Dubey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys. The institution of Dr. Dubey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB . Dr. Dubey has received research support from Department of Defense . Dr. Dubey has received research support from Department of Defense . Dr. Dubey has received research support from UCB. Dr. Dubey has received research support from David J. Tomassoni ALS Research Grant Program . Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care. Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care. Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care. Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care.